Landmark Study of HeartFlow's New Non-Invasive Diagnostic Test Demonstrates High Diagnostic Performance in Patients With Suspected Coronary Artery Disease

Published: Oct 31, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

REDWOOD CITY, Calif. & SAN FRANCISCO--(BUSINESS WIRE)--HeartFlow, Inc. today announced positive data from a study of the company’s newest-generation non-invasive computed fractional flow reserve FFRCT technology. Results from the HeartFlowNXT study demonstrate that, when compared to standard coronary CT angiography (CT) or invasive coronary angiography (ICA), FFRCT provides a more accurate determination of which arterial blockages are associated with coronary ischemia and which are not, suggesting that FFRCT may aid physicians in making decisions regarding further invasive testing or treatment. The study’s findings were presented today in a First Report Investigation session at the 25th Annual Transcatheter Cardiovascular Therapeutics (TCT) meeting in San Francisco.

Help employers find you! Check out all the jobs and post your resume.

Back to news